1. Home
  2. SUPN vs CABO Comparison

SUPN vs CABO Comparison

Compare SUPN & CABO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SUPN
  • CABO
  • Stock Information
  • Founded
  • SUPN 2005
  • CABO 1980
  • Country
  • SUPN United States
  • CABO United States
  • Employees
  • SUPN N/A
  • CABO N/A
  • Industry
  • SUPN Biotechnology: Pharmaceutical Preparations
  • CABO Cable & Other Pay Television Services
  • Sector
  • SUPN Health Care
  • CABO Telecommunications
  • Exchange
  • SUPN Nasdaq
  • CABO Nasdaq
  • Market Cap
  • SUPN 2.1B
  • CABO 1.7B
  • IPO Year
  • SUPN 2012
  • CABO N/A
  • Fundamental
  • Price
  • SUPN $33.05
  • CABO $277.62
  • Analyst Decision
  • SUPN Hold
  • CABO Hold
  • Analyst Count
  • SUPN 2
  • CABO 5
  • Target Price
  • SUPN $36.00
  • CABO $554.40
  • AVG Volume (30 Days)
  • SUPN 464.2K
  • CABO 121.1K
  • Earning Date
  • SUPN 02-25-2025
  • CABO 02-27-2025
  • Dividend Yield
  • SUPN N/A
  • CABO 4.24%
  • EPS Growth
  • SUPN 130.79
  • CABO 847.26
  • EPS
  • SUPN 1.07
  • CABO 38.05
  • Revenue
  • SUPN $651,972,000.00
  • CABO $1,604,144,000.00
  • Revenue This Year
  • SUPN $7.94
  • CABO N/A
  • Revenue Next Year
  • SUPN N/A
  • CABO N/A
  • P/E Ratio
  • SUPN $31.70
  • CABO $7.32
  • Revenue Growth
  • SUPN 6.79
  • CABO N/A
  • 52 Week Low
  • SUPN $25.53
  • CABO $271.19
  • 52 Week High
  • SUPN $40.28
  • CABO $477.65
  • Technical
  • Relative Strength Index (RSI)
  • SUPN 32.98
  • CABO 31.80
  • Support Level
  • SUPN $32.53
  • CABO $276.39
  • Resistance Level
  • SUPN $39.99
  • CABO $295.00
  • Average True Range (ATR)
  • SUPN 1.31
  • CABO 8.92
  • MACD
  • SUPN -0.69
  • CABO 1.51
  • Stochastic Oscillator
  • SUPN 6.71
  • CABO 23.86

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

About CABO Cable One Inc.

Cable One Inc is a telecommunications company. It derives revenue from the provision of broadband, voice, and video services to residential and business customers. From a product perspective, the majority of revenue is sourced from data and video services. This revenue is subscription-based and billed monthly. The company also offers Sparklight TV, an internet protocol-based (IPTV) video service that allows customers with Sparklight TV app to stream video channels from the cloud. The company also derives advertising revenue from selling airtime on its video channels. Voice services are offered over Internet protocols. The company owns a telecommunications infrastructure.

Share on Social Networks: